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Progression of Carotid Plaque Volume Predicts Cardiovascular Events
Wannarong T., Parraga G., Buchanan D., et al. Stroke 2013;44:1859-65.
Conclusion: To potentially assess response to antiatherosclerotic
therapy, measurement of total plaque volume is superior to both measure-
ment of intima-media thickness (IMT) and total plaque area (TPA).
Summary: Progression of IMT, TPA, and total plaque volume (TPV)
have all been advocated as methods for risk prediction of cardiovascular
events. In this study, the authors report a comparison of progression/
regression of carotid IMT, TPA, and TPV in patients attending vascular
prevention clinics. The goal of the study was to determine which variable
could be best used to assess response to antiatherosclerotic therapy. IMT,
TPA, and TPV were measured at baseline in 349 patients attending vascular
prevention clinics. To qualify for enrollment, a TPA of 40 to 600 mm2 was
required. Follow-up was for#5 years (median, 3.17 years). End points were
vascular death, myocardial infarction, stroke, and transient ischemic attacks.
Follow-up measurements at 1 year were available in 323 patients for IMT
and TPA, and in 306 for TPV. Progression of TPV predicted stroke, death,
or transient ischemic attack (TIA) (Kaplan-Meier log-rank P ¼ .001),
stroke/death/myocardial infarction (MI) (P ¼ .008), and stroke/death/
TIA/MI (any cardiovascular event) (P ¼ .001). Progression of TPA weakly
predicted stroke/death/TIA (P ¼ .097) but not stroke/death/MI (P ¼
.59) or any cardiovascular event (P ¼ .143). IMT also did not predict
stroke/death/MI (P ¼ .13) or any cardiovascular event (P ¼ .455). With
adjustment for coronary risk factors, TPV progression remained a signiﬁcant
predictor (P ¼ .001), but a change in TPA did not. Regression of IMT pre-
dicted events (P ¼ .004).
Comment: The data suggest that TPV at the carotid bifurcation
should be considered as the variable of choice to measure response to anti-
atherosclerotic therapy. Interestingly in this study, regression of IMT rather
than progression predicted events. This may be consistent with the growing
thought that IMT is more representative of hypertensive medial hyper-
trophy and is not truly representative of atherosclerosis (Finn AV et al, Arte-
rioscler Thromb Vasc Biol 2010;30:177-81).
Systematic review and meta-analysis of the early and late outcomes of
open and endovascular repair of abdominal aortic aneurysm
Stather PW., Sidloff D., Dattani N., et al. Br J Surg 2013;100:863-72.
Conclusion: There is no long-term survival beneﬁt for patients who
have endovascular aneurysm repair (EVAR) compared with open repairfor abdominal aortic aneurysm (AAA). There are also signiﬁcantly higher
risks of reintervention and aneurysm rupture after EVAR.
Summary: Several randomized controlled trials have documented
a reduction in 30-day operative mortality and hospital length of stay in
favor of EVAR vs open AAA repair. However, medium-term and long-
term follow-up from the trials varies, with some showing early survival
beneﬁt of EVAR lost over time. Registry data have indicated the need
for close surveillance of endografts, with complications arising in 25% to
40% of patients. The inevitable concern is that long-term durability of
EVAR may be inadequate and that there is a signiﬁcant additional cost
of lifelong surveillance after EVAR (Blackhouse G et al, Value Health
2009;12:245-52). Durability and cost issues may therefore negate the early
survival advantage of EVAR (Rutherford RB, Semin Vasc Surg
2012;25:39-48). The authors sought to perform a systematic review and
meta-analysis to investigate “short-, medium- and long-term outcomes,
including morbidity, reintervention and mortality, associated with EVAR
and open aneurysm repair.” Standard PRISMA (Preferred Reporting Items
for Systematic reviews and Meta-Analyses) guidelines were used for the
preparation of this report (Moher D et al, Int J Surg 2010;8:336-41).
Random-effects Mantel-Haenszel meta-analysis was performed to evaluate
mortality and morbidity outcomes. The data were derived from existing
published randomized trials, and information from Medicare and Swed-
Vasc databases was also included. The result included 25,078 patients
undergoing EVAR and 27,142 undergoing open repair for AAA. The
EVAR patients had signiﬁcantly lower 30-day or in-hospital mortality
(1.3% vs 4.7% for open repair; odds ratio [OR] 0.36; 95% conﬁdence
interval [CI], 0.21-0.61; P < .001). By the 2-year follow-up, there was
no difference in all-cause mortality (14.3% vs 15.2%; OR, 0.87, 95% CI,
0.72-1.06; P ¼ 0.17). This was maintained after at least 4 years of
follow-up (34.7% vs 33.8%; OR, 1.11; 95% CI, 0.91-1.35; P ¼ .30). There
was no signiﬁcant difference in aneurysm-related mortality by follow-up of
2 years or longer. A signiﬁcantly higher proportion of patients undergoing
EVAR required reintervention (P ¼ .003) and suffered aneurysm rupture
(P < .001).
Comment: The debate regarding the overall efﬁcacy of EVAR vs
open repair of AAA continues. EVAR enthusiasts will counter that the
procedure will improve with engineering advances of the devices. Enthusi-
asts for open repair will point out that in many centers, open repair of
infrarenal AAA performed electively has a <4% mortality and that late
rupture after open repair is distinctly unusual. Articles such as this are
academically interesting, but the fact of matter is this genie is long out of
the bottle. There are too many factors driven by physicians, patients, and
industry to change things in the near future. EVAR will continue to be
the preferred method for infrarenal AAA repair unless the procedure is
limited by mandates from public health ofﬁcials and payers.
